scholarly journals Parents’ Use of Internal State Language with Toddlers at High and Low Genetic Risk for Autism Spectrum Disorder

2018 ◽  
Vol 49 (4) ◽  
pp. 1366-1377 ◽  
Author(s):  
Susan B. Campbell ◽  
Amanda S. Mahoney ◽  
Celia A. Brownell ◽  
Elizabeth L. Moore ◽  
Amy B. Tavares
2019 ◽  
Vol 42 (1) ◽  
pp. 3-11
Author(s):  
Bridget M. Wright ◽  
Joann P. Benigno ◽  
Jamie B. Boster ◽  
John W. McCarthy ◽  
Bridget K. Coologhan

Thirty-one children with and without autism spectrum disorder were asked to draw the meaning of 10 basic concepts. Following each drawing, children explained their drawing to the experimenter. Transcripts of the drawing task were coded for children’s use of personal pronouns and internal state terms. Children’s use of on- and off-task comments while explaining each drawing was examined. Both groups of children had a longer mean length of utterance when prompted to explain their drawings than while they were drawing. Analyses revealed no significant differences between children with and without autism in their use of internal state terms, pronouns, or their use of on- and off-task language during the drawing task. Clinical implications for the use of drawings as expressive language supports for children with autism are discussed.


2019 ◽  
Vol 51 (3) ◽  
pp. 431-444 ◽  
Author(s):  
Jakob Grove ◽  
◽  
Stephan Ripke ◽  
Thomas D. Als ◽  
Manuel Mattheisen ◽  
...  

2015 ◽  
Vol 45 (11) ◽  
pp. 3594-3605 ◽  
Author(s):  
Susan B. Campbell ◽  
Nina B. Leezenbaum ◽  
Emily N. Schmidt ◽  
Taylor N. Day ◽  
Celia A. Brownell

2021 ◽  
Vol 12 ◽  
Author(s):  
Yaowaluck Hongkaew ◽  
Andrea Gaedigk ◽  
Bob Wilffert ◽  
Roger Gaedigk ◽  
Wiranpat Kittitharaphan ◽  
...  

We investigated the association between genetic variations in pharmacodynamic genes and risperidone-induced increased prolactin levels in children and adolescents with autism spectrum disorder (ASD). In a retrospective study, variants of pharmacodynamic genes were analyzed in 124 ASD patients treated with a risperidone regimen for at least 3 months. To simplify genotype interpretation, we created an algorithm to calculate the dopamine D2 receptor (DRD2) gene genetic risk score. There was no relationship between prolactin levels and single SNPs. However, the H1/H3 diplotype (A2/A2-Cin/Cin-A/G) of DRD2/ankyrin repeat and kinase domain containing 1 (ANKK1) Taq1A, DRD2 -141C indel, and DRD2 -141A>G, which had a genetic risk score of 5.5, was associated with the highest median prolactin levels (23 ng/ml). As the dose-corrected plasma levels of risperidone, 9-OH-risperidone, and the active moiety increased, prolactin levels in patients carrying the H1/H3 diplotype were significantly higher than those of the other diplotypes. DRD2 diplotypes showed significantly high prolactin levels as plasma risperidone levels increased. Lower levels of prolactin were detected in patients who responded to risperidone. This is the first system for describing DRD2 haplotypes using genetic risk scores based on their protein expression. Clinicians should consider using pharmacogenetic-based decision-making in clinical practice to prevent prolactin increase.


Author(s):  
Jarle Johannessen ◽  
Terje Nærland ◽  
Sigrun Hope ◽  
Tonje Torske ◽  
Anett Kaale ◽  
...  

AbstractClinical relevance of genetic testing is increasing in autism spectrum disorder (ASD). Information about genetic risk may contribute to improved diagnostics, treatment and family planning, but may also be perceived as a burden. Knowledge about the families’ preferences with regard to genetic risk information is important for both health care professionals and policy makers. We investigated attitudes towards sharing information about genetic risk of ASD and knowledge about future health among parent members of the Norwegian Autism Association (N = 1455) using a questionnaire, and the relationships with parent and child characteristics, such as age, gender and ASD severity. Most preferred autonomy in deciding whom to inform about genetic risk of ASD (74.4%) and a minority supported extensive intra-familial disclosure of the genetic risk (41.1%). The majority agreed that it is an obligation to know as much as possible relevant for future health (58.0%) and only 51.7% agreed to a principle of a ‘right not to know’. In regression models, the attitudes were associated with opinions about benefits and harms of genetic testing (e.g., treatment, family planning, understanding of ASD pathology, insurance discrimination and family conflict). In sum, the findings show that most parents want to know as much as possible relevant for their children’s future health and keep their autonomy and intra-familial confidentiality about genetic risk information. Nearly half of the parents were not concerned with a “right not to know”. These attitudes can inform development of guidelines and bioethics in the age of genomic precision medicine.


Sensors ◽  
2018 ◽  
Vol 18 (12) ◽  
pp. 4271 ◽  
Author(s):  
Mohammed Taj-Eldin ◽  
Christian Ryan ◽  
Brendan O’Flynn ◽  
Paul Galvin

The goal of real-time feedback on physiological changes, stress monitoring and even emotion detection is becoming a technological reality. People in their daily life experience varying emotional states, some of which are negative and which can lead to decreased attention, decreased productivity and ultimately, reduced quality of life. Therefore, having a solution that continuously monitors the physiological signals of the person and assesses his or her emotional well-being could be a very valuable tool. This paper aims to review existing physiological and motional monitoring devices, highlight their features and compare their sensing capabilities. Such technology would be particularly useful for certain populations who experience rapidly changing emotional states such as people with autism spectrum disorder and people with intellectual disabilities. Wearable sensing devices present a potential solution that can support and complement existing behavioral interventions. This paper presents a review of existing and emerging products in the market. It reviews the literature on state-of-the-art prototypes and analyzes their usefulness, clinical validity, and discusses clinical perspectives. A small number of products offer reliable physiological internal state monitoring and may be suitable for people with Autism Spectrum Disorder (ASD). It is likely that more promising solutions will be available in the near future. Therefore, caregivers should be careful in their selection of devices that meet the care-receiver’s personal needs and have strong research support for reliability and validity.


Sign in / Sign up

Export Citation Format

Share Document